Fibrosis Clinical Trials

496 recruitingLast updated: June 17, 2026

There are 496 actively recruiting fibrosis clinical trials across 69 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Birmingham, Alabama, United States. Updated daily from ClinicalTrials.gov.


Fibrosis Trials at a Glance

496 actively recruiting trials for fibrosis are listed on ClinicalTrialsFinder across 6 cities in 69 countries. The largest study group is Phase 2 with 104 trials, with the heaviest enrollment activity in Boston, New York, and Birmingham. Lead sponsors running fibrosis studies include Hospices Civils de Lyon, Assistance Publique - Hôpitaux de Paris, and Massachusetts General Hospital.

Treatments under study

About Fibrosis Clinical Trials

Looking for clinical trials for Fibrosis? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Fibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 496 trials

Recruiting

A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

Non-cystic Fibrosis Bronchiectasis
AstraZeneca320 enrolled38 locationsNCT07245407
Recruiting

Role of Genetic Factors in the Development of Lung Disease

AsthmaCystic FibrosisPulmonary Fibrosis+2 more
National Heart, Lung, and Blood Institute (NHLBI)3,500 enrolled2 locationsNCT00001532
Recruiting
Not Applicable

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

Liver FibrosisNon-alcoholic Fatty Liver Disease NAFLDAlcoholic Liver Disease (ALD)
University Hospital, Angers1,788 enrolled13 locationsNCT05699018
Recruiting

ARPKD Database Study

Autosomal Recessive Polycystic Kidney DiseaseNephronophthisisCongenital Hepatic Fibrosis+7 more
Children's Hospital of Philadelphia200 enrolled6 locationsNCT01401998
Recruiting
Phase 2

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

Non-cystic Fibrosis Bronchiectasis
Sanofi70 enrolled3 locationsNCT07547436
Recruiting
Phase 1

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Novartis Pharmaceuticals6 enrolled7 locationsNCT07340138
Recruiting
Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Contineum Therapeutics324 enrolled22 locationsNCT07284459
Recruiting
Phase 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Mediar Therapeutics164 enrolled69 locationsNCT06967805
Recruiting
Phase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled373 locationsNCT06238622
Recruiting
Phase 3

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled13 locationsNCT07357727
Recruiting
Phase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled526 locationsNCT06632444
Recruiting
Phase 2

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Cystic Fibrosis (CF)Exocrine Pancreatic Insufficiency (EPI)
Anagram Therapeutics, Inc.113 enrolled26 locationsNCT07450547
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting
Phase 2

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim71 enrolled46 locationsNCT07036523
Recruiting

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

SarcoidosisIdiopathic Pulmonary FibrosisInterstitial Lung Diseases+1 more
University of Chicago4,000 enrolled1 locationNCT00470327
Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Primary myelofibrosis (PMF)Post-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Prelude Therapeutics100 enrolled5 locationsNCT07469891
Recruiting
Not Applicable

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

Non-cystic Fibrosis Bronchiectasis
Physio-Assist622 enrolled57 locationsNCT06487273
Recruiting
Phase 3

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

MASH With FibrosisNASH With Fibrosis
Akero Therapeutics, Inc1,650 enrolled356 locationsNCT06215716
Recruiting
Phase 2

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics120 enrolled16 locationsNCT06968845
Recruiting
Phase 3

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Progressive Pulmonary FibrosisInterstitial Lung Disease
United Therapeutics698 enrolled159 locationsNCT05943535